Selective benzimidazole inhibitors of the antigen receptor-mediated NF-κB activation pathway

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 5, 2010, Pages 1918-1924

  Okolotowicz, Karl J ^a   Shi, Ranxin ^b   Zheng, Xueying ^a   MacDonald, Mary ^a   Reed, John C ^b   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Antigen receptor mediated; Benzimidazoles; Library synthesis; Medicinal chemistry optimization; Nf B

Indexed keywords

1 (3,5 DITERT BUTYL 4 HYDROXYPHENYL) 2 [2 (BUTYLAMINO)5,6 DIMETHYL 1H BENZ[D]IMIDAZOL 1 YL]ETHANONE; 1 (3,5 DITERT BUTYL 4 METHOXYPHENYL) 2 [2 (3 HYDROXYPROPYLAMINO) 5,6 DIMETHYL 1H BENZ[D]IMIDAZOL 1 YL]ETHANONE; 2 [2 (3 HYDROXYPROPYLAMINO) 5,6 DIMETHYL 1H BENZ[D]IMIDAZOL 1 YL] 1 (3,5 DITERT BUTYL 4 HYDROXYPHENYL)ETHANONE; 2 [2 (3 METHOXYPROPYLAMINO) 5,6 DIMETHYL 1H BENZ[D]IMIDAZOL 1 YL] 1 (3,5 DITERT BUTYL 4 HYDROXYPHENYL)ETHANONE; 2 [2 (3 METHOXYPROPYLAMINO) 5,6 DIMETHYL 1H BENZ[D]IMIDAZOL 1 YL] 1 (3,5 DITERT BUTYL 4METHOXYPHENYL)ETHANONE; BENZIMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

BENZIMIDAZOLES; HUMANS; MICROSOMES, LIVER; NF-KAPPA B; RECEPTORS, ANTIGEN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTIONAL ACTIVATION;

EID: 77249179133     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.01.039     Document Type: Article

References (21)

1. Hsu H., Xiong J., and Goeddel D.V. Cell 81 (1995) 495
2. Fotin-Mleczek M., Henkler F., Hausser A., Glauner H., Samel D., Graness A., Scheurich P., Mauri D., and Wajant H. J. Biol. Chem. 279 (2004) 677
3. West A.P., Koblansky A.A., and Ghosh S. Annu. Rev. Cell Dev. Biol. 22 (2006) 409
4. Fujita T. Science 314 (2006) 935
5. Janssens S., and Tschopp J. Cell Death Differ. 13 (2006) 773
6. Hasegawa M., Fujimoto Y., Lucas P.C., Nakano H., Fukase K., Nunez G., and Inohara N. EMBO J. 27 (2008) 373
7. Schulze-Luehrmann J., and Ghosh S. Immunity 25 (2006) 701
8. Lu M., Lin S.C., Huang Y., Kang Y.J., Rich R., Lo Y.C., Myszka D., Han J., and Wu H. Mol. Cell 26 (2007) 689
9. Hayden M.S., West A.P., and Ghosh S. Oncogene 25 (2006) 6758
10. Thome M. Nat. Rev. Immunol. 4 (2004) 348
11. Gilmore T.D., and Herscovitch M. Oncogene 25 (2006) 6887
12. Shi, R.; Re, D.; Dudl, E.; Cuddy, M.; Okolotowicz, K. J.; Dahl, R.; Su, Y.; Hurder, A.; Kitada, S.; Peddibhotla, M.; Roth, G.; Smith, L.; Kipps, T. J.; Cosford, N.; Cashman, J. R.; Reed, J. C. ACS Chem. Biol., 2010, accepted for publication.
13. ∼60,000 compounds were screened at The Scripps Research Institute from the NIH compound collection (http://mlsmr.glpg.com/MLSMR_HomePage/) and ∼52,000 compounds were screened at The Burnham Institute for Medical Research's small molecule collection (http://bccg.burnham.org/Assays/ScreeningCompoundCollection.aspx).
14. VanAllan J.A., and Deacon B.D. Org. Synth. 4 (1963) 569
15. Yu M.J., McCowan J.R., Thrasher K.J., Keith P.T., Luttman C.A., Ho P.P.K., Towner R.D., Bertach B., Horng J.S., Um S.L., Phebus L.A., and Saunders R.D. J. Med. Chem. 35 (1992) 716
16. Anisimova V.A., Tolpygin I.E., Spasov A.A., Kosolapov V.A., Stepanov A.V., Orlova A.A., and Naumenko L.V. Khim.-Farmatsevticheskii Zh. 41 (2007) 9
17. Franklin M.R., and Constance J.E. Drug Metab. Rev. 39 (2007) 309
18. Hutzler J.M., Melton R.J., Rumsey J.M., Schnute M.E., Locuson C.W., and Wienkers L.C. Chem. Res. Toxicol. 19 (2006) 1650
19. Denton T.T., Zhang X., and Cashman J.R. Biochem. Pharmacol. 67 (2004) 751
20. Kamath A.V., Wang J., Lee F.Y., and Marathe P.H. Cancer Chemother. Pharmacol. 61 (2008) 365
21. Wen X., and Walle T. Drug Metab. Dispos. 34 (2006) 1786